To determine the genetic basis of autosomal dominant neurohypophyseal diabetes insipidus (ADNDI) in a Cypriot family, we ascertained and studied a large, four-generation kindred in which all participating family members had arginine vasopressin-neurophysin II (AVP-NP-II) gene analyses done. A G to A transition was found by DNA sequence analysis at position 1773 (G1773A) of the AVP-NPII gene which is predicted to encode a substitution of tyrosine for cysteine in codon 59 (CYS59TYR). The mutation was confirmed by restriction endonuclease analysis of PCR amplification products that contain the corresponding segment of the AVP-NPII gene. To clarify the morphologic status of the pituitaries of family members, 12 affected and 3 nonaffected members had magnetic resonance imaging (MRI) studies. The bright spot of the posterior pituitary lobe was completely absent in 75% and faintly identified in 25% of the affected members who were examined with MRI. We conclude that (1) a novel G1773A transition in exon 2 of the AVP-NPII gene causes ADNDI in the large Cypriot kindred studied, (2) this mutation is predicted to encode a CYS59TYR substitution in NPII, and (3) MRI studies of the posterior pituitary lobes of affected family members show either a decreased intensity or a complete absence of the bright spot in all cases studied.

Keywords:
Neurohypophyseal diabetes insipidus, AVP-NPII gene, Pituitary
1.
Baylis PH, Robertson GL: Vasopressin function in familial central diabetes insipidus. Postgrad Med J 1981;57:36–40.
2.
Repaske DR, Philips JA III: The molecular biology of human hereditary central diabetes insipidus. Prog Brain Res 1992;93:295–308.
3.
Kaplowitz PB, D’Ercole AJ, Robertson GI: Radioimmunoassay of vasopressin in familial central diabetes insipidus. J Pediatr 1982;100:76–81.
4.
Fujisawa I, Asato R, Nishimura K, Togashi K, Itoh K, Nakano Y, Itoh H, Hashimoto N, Takeuchi J, Torizuka K: Anterior and posterior lobes of the pituitary gland: Assessment by 1.5 T imaging. J Comput Assist Tomogr 1987;11:214–220.
5.
Colombo N, Berry I, Kucharczyk J, Kucharczyk W, de Groot J, Larson T, Norman D, Newton TH: Posterior pituitary gland: Appearance on MR images in normal and pathologic states. Neuroradiology 1987;165:481–485.
6.
Maghnie M, Villa A, Arico M, Larizza D, Pezzotta S, Beluffi G, Genovese E, Severi F: Correlation between magnetic resonance imaging of posterior pituitary and neurohypophyseal function in children with diabetes insipidus. J Clin Endocrinol Metab 1992;74:795–800.
7.
Miyamoto S, Sasaki N, Tanabe Y: Magnetic resonance imaging in familial central diabetes insipidus. Neuroradiology 1991;33:272–273.
8.
Sausville E, Carney D, Battey J: The human vasopressin gene is linked to the oxytocin gene and is selectively expressed in a cultured lung cancer cell line. J Biol Chem 1985;260:10236–10244.
9.
Brownstein MJ: Biosynthesis of vasopressin and oxytocin. Annu Rev Physiol 1983;45:129–135.
10.
Chen LQ, Rose JP, Breslow E, Yang D, Chang WR, Furey WF Jr, Sax M, Wang BC: Crystal structure of a bovine neurophysin II dipeptide complex at 2.8 Å determined from the single wavelength anomalous scattering signal of an incorporated iodine atom. Proc Natl Acad Sci USA 1991;88:4240–4244.
11.
Breslow E, Burman S: Molecular, thermodynamic and biological aspects of recognition and function in neurophysin-hormone systems: A model system for the analysis of protein-peptide interactions. Adv Enzymol Relat Areas Mol Biol 1990;63:1–67.
12.
Fujisawa I, Asato R, Kawata M, Sano Y, Nakao K, Yamada T, Imura H, Naito Y, Hoshino K, Noma S, Kakano Y, Konishi J: Hyperintense signal of the posterior pituitary on T1-weighted MR images: An experimental study. J Comput Assist Tomogr 1989;13:371–377.
13.
Mark LP, Haughton VM, Hendrix LE, Daniels DL, Williams AL, Czervionke LF, Asleson RJ: High intensity signals within the posterior pituitary fossa: A study with fat-suppression MR techniques. Am J Neuroradiol 1991;12:529–532.
14.
Moses AM: Use of T1-weighted MR imaging to differentiate between primary polydipsia and central diabetes insipidus. Am J Neuroradiol 1992;13:1273–1277.
15.
Rutishauser J, Boni-Schnetzler M, Boni J, Wichmann W, Huisman T, Vallotton MB, Froesch ER: A novel point mutation in the translation initiation codon of the pre-pro-vasopressin-neurophysin II gene: Cosegregation with morphological abnormalities and clinical symptoms in autosomal dominant neurohypophyseal diabetes insipidus. J Clin Endocrinol Metab 1996;81:192–198.
16.
Repaske DR, Philips JA III, Kirby PT, Tze WJ, D’Ercole AJ, Battey J: Molecular analysis of autosomal dominant neurohypophyseal diabetes insipidus. J Clin Endocrinol Metab 1990;70:752–757.
17.
Ritting S, Robertson GL, Siggaard C, Kovacs L, Gregersen N, Nyborg J, Pedersen EB: Identification of 13 new mutations in the vasopressin-neurophysin II gene in 17 kindreds with familial autosomal dominant neurohypophyseal diabetes insipidus. Am J Hum Genet 1996;58:107–117.
18.
Rauch F, Lenzpep C, Nurnberg P, Prommel C, Vetter U: A novel mutation in the coding region for neurophysin-II is associated with autosomal dominant neurohypophyseal diabetes insipidus. Clin Endocrinol 1996;44:45–54.
19.
Yuasa H, Ito M, Nagasaki H, Oiso Y, Miyamoto S, Sasaki N, Saito H: Glu-47, which forms a salt bridge between neurophysin-II and arginine vasopressin, is deleted in patients with familial central diabetes insipidus. J Clin Endocrinol Metab 1993;77:600–604.
20.
Repaske DR, Summar ML, Krishnamani MR, Gultekin EK, Arriazu MC, Roubicek ME, Blanco M Isaac GB, Phillips JA III: Recurrent mutations in the vasopressin-neurophysin II gene cause autosomal dominant neurohypophyseal diabetes insipidus. J Clin Endocrinol Metab 1996;81:2328–2334.
21.
Repaske DR, Medlej R, Gultekin EK, Krishnamani MR, Halaby G, Findling JW, Phillips JA III: Heterogeneity in clinical manifestation of autosomal dominant neurohypophyseal diabetes insipidus caused by a mutation encoding Ala-1 Val in the signal peptide of the arginine vasopressin/neurophysin II/copeptin precursor. J Clin Endocrinol Metab 1997;82:51–56.
22.
Ueta Y, Taniguchi S, Yoshida A, Murakami I, Mitani Y, Hisatome I, Manabe I, Sato R, Tszboi M: A new type of familial central diabetes insipidus caused by a single base substitution in the neurophysin II coding region of the vasopressin gene. J Clin Endocrinol Metab 1996;81:1787–1790.
23.
Nagasaki H, Ito M, Yuasa H, Saito H, Fukase M, Hamada K, Ishikawa E, Katakami H, Oiso Y: Two novel mutations in the coding region for neurophysin-II associated with familial central diabetes insipidus. J Clin Endocrinol Metab 1995;80:1352–1356.
24.
Bahnse U, Oosting P, Swaab DF, Nahke P, Richter D, Schmale H: A missense mutation in the vasopressin-neurophysin precursor gene cosegregates with human autosomal dominant neurohypophyseal insipidus. EMBO J 1992;11:19–23.
25.
Ito M, Mori Y, Oiso Y, Saito H: A single base substitution in the coding region for neurophysin II associated with familial central diabetes insipidus. J Clin Invest 1991;87:725–728.
26.
Krishnamani MRS, Phillips JA III, Copeland KC: Detection of an novel arginine vasopressin defect by dideoxy fingerprinting. J Clin Endocrinol Metab 1993;77:596–598.
27.
McLeod JF, Kovacs L, Gaskill MB, Rittig S, Bradley GS, Robertson GL: Familial neurohypophyseal diabetes insipidus associated with a signal peptide mutation. J Clin Endocrinol Metab 1993;77:599A–599G.
28.
Nagasaki H, Ito M, Yuasa H, Saito H, Fukase M, Hamada K, Ishikawa E, Katakami H, Oiso Y: Two novel mutations in the coding region for neurophysin-II associated with familial central diabetes insipidus. J Clin Endocrinol Metab 1995;80:1352–1356.
29.
Gagliardi PC, Bernasconi S, Repaske DR: Autosomal dominant neurohypophyseal diabetes insipidus associated with a missense mutation encoding Gly23 Val in neurophysin II. J Clin Endocrinol Metab 1997;82:3643–3646.
30.
Calvo B, Bilbao JR, Urrutia I, Eizaguirre J, Gaztambide S, Castano L: Identification of a novel nonsense mutation and a missense substitution in the vasopressin-neurophysin II gene in two Spanish kindreds with familial neurohypophyseal diabetes insipidus. J Clin Endocrinol Metab 1998;83:995–997.
31.
Grant FD, Ahmadi A, Hosley CM, Majoub JA: Two novel mutations of the vasopressin gene associated with familial diabetes insipidus and identification of an asymptomatic carrier infant. J Clin Endocrinol Metab 1998;83:3958–3963.
32.
Calvo B, Bilbao R, Rodríguez A, Rodríguez-Arnao MD, Castaño L: Molecular analysis in familial neurohypophyseal diabetes insipidus: Early diagnosis of an asymptomatic carrier. J Clin Endocrinol Metab 1999;84:3351–3353.
33.
Miller M, Dalakos T, Moses AM, Fellerman H, Streelen DHP: Recognition of partial defects in antidiuretic hormone secretion. Ann Intern Med 1970;73:721–729.
34.
Braverman LE, Mancini JP, McGoldrich DM: Hereditary idiopathic diabetes insipidus. A case report with autopsy findings. Ann Intern Med 1965;63:503–508.
35.
Green JR, Buchan GC, Alvord EC Jr, Swanson AG: Hereditary and idiopathic types of diabetes insipidus. Brain 1967;90:707–714.
36.
Brooks BS, El Gammal T, Allison JD, Hoffmann WH: Frequency and variation of the posterior pituitary bright signal on MR images. Am J Neuroradiol 1989;10:943–948.
37.
Gudinchet F, Brunelle F, Barth MO, Taviere V, Brauner R, Rappaport R, Lallemand D: MR imaging of the posterior hypophysis in children. AJR 1989;153:351–354.
38.
Sato N, Ishizaka H, Yagi H, Matsomoto M, Endo K: Pituitary in diabetes insipidus: Dynamic MR imaging radiology. Radiology 1993;186:357–360.
39.
Tien R, Kucharczyk J, Kucharczyk W: MR imaging patients with diabetes insipidus. Am J Neuroradiol 1991;12:533–542.
40.
Mark I, Pech P, Daniela D, Charles C, Williams A, Hanghton V: The pituitary fossa: A correlative anatomic and MR study. Radiology 1984;153:453–457.
41.
Kucharczyk J, Kucharczyk W, Berry I, de Groot J, Kelly W, Norman D, Newton TH: Histochemical characterization and functional significance of the hyperintense signal on MR images of the posterior pituitary. AJR 1989;152:153–157.
42.
Fujisawa I, Asato R, Kawata M: Hyperintense signal of the posterior pituitary on T1-weighted MR images: An experimental study. J Comput Assist Tomogr 1989;13:371–377.
43.
Huang HB, Breslow E: Identification of the unstable neurophysin disulfide and localization to the hormone-binding site. Relationship to folding-unfolding pathways. J Biol Chem 1992;267:6750–6756.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.